AVA6000 Elicits Clinically Meaningful Tumor Shrinkage in Salivary Gland Cancer
Preliminary data show that AVA6000 led to robust and clinically meaningful tumor shrinkage in patients with salivary gland cancer.
Related Articles
Anito-Cel Demonstrates Safety and Early Efficacy in R/R Multiple Myeloma
Anitocabtagene autoleucel generated durable response in patients with relapsed/refractory multiple myeloma.
There’s and App for That: Lessons from Willy Loman
Most of us live in a blistering, hyper-caffeinated digital tornado where everything is due yesterday, time and space are totally irrelevant.
Trump calls for U.S. to withdraw from World Health Organization
The move to exit the WHO is historic and controversial. The U.S. has long been the most generous provider of humanitarian assistance.
‘Publish or perish’ culture blamed for reproducibility crisis
Nature – Survey of more than 1,600 biomedical researchers also flagged small sample sizes and cherry-picking of data as leading causes of reproducibility problems.
Iparomlimab/Tuvonralimab Plus Chemo ± Bevacizumab Yields Responses in Recurrent/Metastatic Cervical Cancer
First-line paromlimab/tuvonralimab plus chemotherapy with or without bevacizumab was active in recurrent/metastatic cervical cancer.
Executive Order 14087—Lowering Prescription Drug Costs for Americans | The American Presidency Project
By the authority vested in me as President by the Constitution and the laws of the United State s of America, it is hereby ordered…
Trump calls for U.S. to withdraw from World Health Organization
The move to exit the WHO is historic and controversial. The U.S. has long been the most generous provider of humanitarian assistance.
Candidates for the AACR Board of Directors
Official candidates for the AACR election of Board of Directors, serving 2024-2027.
Trump calls for U.S. to withdraw from World Health Organization
The move to exit the WHO is historic and controversial. The U.S. has long been the most generous provider of humanitarian assistance.
Dr Nathanson on BRCA1/2 Reversion Mutations in Response to Therapy in Breast Cancer
Katherine L. Nathanson, MD, discusses the identification of reversion mutations in BRCA1/2 in response to therapy among patients with breast cancer.